Oxazoles

• 

  Subject Areas on Research

  • A closer inspection of tedizolid - authors' reply. 
  • A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. 
  • Assignment of 1H, 13C and 15N backbone resonances of Escherichia coli LpxC bound to L-161,240. 
  • Berninamycin. 2. Products of acidic hydrolysis, methanolysis, and acetolysis of berninamycin A1. 
  • Bimatoprost, prostamide activity, and conventional drainage. 
  • Bioreduction of nitroxides by Staphylococcus aureus. 
  • Casein kinase I in the mammalian circadian clock. 
  • Chiral action at a distance: remote substituent effects on the optical activity of calyculins A and B. 
  • Dephosphorylation of ezrin as an early event in renal microvillar breakdown and anoxic injury. 
  • Design, synthesis, and study of a mycobactin-artemisinin conjugate that has selective and potent activity against tuberculosis and malaria. 
  • Effect of famoxadone on photoinduced electron transfer between the iron-sulfur center and cytochrome c1 in the cytochrome bc1 complex. 
  • Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney. 
  • Enantioselective Intermolecular Addition of Aliphatic Amines to Acyclic Dienes with a Pd-PHOX Catalyst. 
  • Enantioselective diene Cyclization/Hydrosilylation catalyzed by optically active palladium bisoxazoline and pyridine-oxazoline complexes. 
  • Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. 
  • Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. 
  • Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. 
  • Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2. 
  • Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. 
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. 
  • Maleimide-Functionalized Poly(2-Oxazoline)s and Their Conjugation to Elastin-Like Polypeptides. 
  • Mitotic phosphatase activity is required for MCC maintenance during the spindle checkpoint. 
  • Monocytoid differentiation of freshly isolated human myeloid leukemia cells and HL-60 cells induced by the glutamine antagonist acivicin. 
  • N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. 
  • N-methylated 5-alkenyloxazolium salt transformations. 
  • Optical signatures of molecular dissymmetry: combining theory with experiments to address stereochemical puzzles. 
  • PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. 
  • Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. 
  • Phosphorylation of PDZ1 domain attenuates NHERF-1 binding to cellular targets. 
  • Protein phosphatases mediate depotentiation induced by high-intensity theta-burst stimulation. 
  • Regulation of casein kinase I epsilon and casein kinase I delta by an in vivo futile phosphorylation cycle. 
  • Simultaneous stretching and contraction of stress fibers in vivo. 
  • Structural basis of the promiscuous inhibitor susceptibility of Escherichia coli LpxC. 
  • Synthetic and model computational studies of molar rotation additivity for interacting chiral centers: a reinvestigation of van't Hoff's principle. 
  • Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. 
  • Three ring posttranslational circuses: insertion of oxazoles, thiazoles, and pyridines into protein-derived frameworks. 
  • Total synthesis of (-)-hennoxazole A. 
  • Total synthesis of (-)-hennoxazole A. 
  • Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.